- Home
- CLLS vs EIC Comparison
CLLS vs EIC Comparison
Compare CLLS & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- EIC
- Stock Information
- Founded
- CLLS 1999
- EIC N/A
- Country
- CLLS France
- EIC United States
- Employees
- CLLS N/A
- EIC N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- EIC Finance/Investors Services
- Sector
- CLLS Health Care
- EIC Finance
- Exchange
- CLLS Nasdaq
- EIC Nasdaq
- Market Cap
- CLLS 240.2M
- EIC 242.6M
- IPO Year
- CLLS 2007
- EIC 2019
- Fundamental
- Price
- CLLS $2.04
- EIC $16.24
- Analyst Decision
- CLLS Buy
- EIC
- Analyst Count
- CLLS 2
- EIC 0
- Target Price
- CLLS $8.00
- EIC N/A
- AVG Volume (30 Days)
- CLLS 23.1K
- EIC 116.0K
- Earning Date
- CLLS 11-04-2024
- EIC 11-14-2023
- Dividend Yield
- CLLS N/A
- EIC 13.63%
- EPS Growth
- CLLS N/A
- EIC N/A
- EPS
- CLLS N/A
- EIC 0.80
- Revenue
- CLLS $19,635,000.00
- EIC N/A
- Revenue This Year
- CLLS $271.02
- EIC N/A
- Revenue Next Year
- CLLS $33.48
- EIC N/A
- P/E Ratio
- CLLS N/A
- EIC $20.31
- Revenue Growth
- CLLS N/A
- EIC N/A
- 52 Week Low
- CLLS $0.96
- EIC $13.00
- 52 Week High
- CLLS $3.77
- EIC $16.48
- Technical
- Relative Strength Index (RSI)
- CLLS 44.35
- EIC 58.35
- Support Level
- CLLS $1.95
- EIC $16.35
- Resistance Level
- CLLS $2.06
- EIC $16.58
- Average True Range (ATR)
- CLLS 0.10
- EIC 0.15
- MACD
- CLLS -0.01
- EIC 0.03
- Stochastic Oscillator
- CLLS 40.97
- EIC 53.27
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.